deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT02088060

A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients

Sponsor: Central Institute of Mental Health, Mannheim

Conditions Schizophrenia
Updated 13 times since 2017 Last updated: Dec 19, 2024 Started: Dec 8, 2015 Primary completion: Sep 16, 2024 Completion: Sep 16, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Following the expiry of the original research grant, no follow-up financing could be provided to complete the study.

This PHASE2 trial investigates Schizophrenia and is currently terminated or withdrawn. Central Institute of Mental Health, Mannheim leads this study, which shows 13 recorded versions since 2015 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

~Jan 2017 – ~Mar 2018 · 14 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~Jan 2021 · 16 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Nov 2022 · 18 months · monthly snapshot~Nov 2022 – ~May 2023 · 6 months · monthly snapshot~May 2023 – ~Feb 2024 · 9 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Jan 2025 — Sep 2025 [monthly]

    Terminated PHASE2

    Status: Active Not RecruitingTerminated

  3. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown StatusActive Not Recruiting

Show 8 earlier versions
  1. May 2023 — Feb 2024 [monthly]

    Unknown Status PHASE2

    Status: Active Not RecruitingUnknown Status

  2. Nov 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  3. May 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  8. Jan 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Central Institute of Mental Health, Mannheim
  • Glostrup University Hospital, Copenhagen
  • Heidelberg University
  • Ludwig-Maximilians - University of Munich
  • Martin-Luther-Universität Halle-Wittenberg
  • Technical University of Munich
Data source: Central Institute of Mental Health, Mannheim

For direct contact, visit the study record on ClinicalTrials.gov .